A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.

doi:10.1038/s41467-021-25904-w

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.

Nature communications - 22 Sept 2021

Konstantinopoulos Panagiotis A, da Costa Alexandre André B A, Gulhan Doga, Lee Elizabeth K, Cheng Su-Chun, Hendrickson Andrea E Wahner, Kochupurakkal Bose, Kolin David L, Kohn Elise C, Liu Joyce F, Stover Elizabeth H, Curtis Jennifer, Tayob Nabihah, Polak Madeline, Chowdhury Dipanjan, Matulonis Ursula A, Färkkilä Anniina, D'Andrea Alan D, Shapiro Geoffrey I

Abstract excerpt

In a trial of patients with high grade serous ovarian cancer (HGSOC), addition of the ATR inhibitor berzosertib to gemcitabine improved progression free survival (PFS) compared to gemcitabine alone but biomarkers predictive of treatment are lacking. Here we report a candidate biomarker of response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in HGSOC ovarian cancer. Patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Gemcitabine

Share to Isoxazoles

Share to Progression-Free Survival

Share to Pyrazines

Share to Recombinational DNA Repair

Share to Retinoblastoma Binding Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 34552099
DOI: 10.1038/s41467-021-25904-w
PMCID: PMC8458434

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.PMID 34552099Read ↗

Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging AgentsSemantic proximity Read ↗

Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancerSemantic proximity Read ↗

AKT1 interacts with DHX9 to Mitigate R Loop–Induced Replication Stress in Ovarian CancerSemantic proximity Read ↗

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancerSemantic proximity Read ↗

A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors.Semantic proximity Read ↗

Interferon Beta Drives Therapy Resistance in a Patient-Derived Model of High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Co-regulation and functional cooperativity of FOXM1 and RHNO1 bidirectional genes in ovarian cancerSemantic proximity Read ↗

ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancersSemantic proximity Read ↗

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP InhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.